- Home
- FUNC vs IVA Comparison
FUNC vs IVA Comparison
Compare FUNC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUNC
- IVA
- Stock Information
- Founded
- FUNC 1900
- IVA 2011
- Country
- FUNC United States
- IVA France
- Employees
- FUNC N/A
- IVA N/A
- Industry
- FUNC Major Banks
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- FUNC Finance
- IVA Health Care
- Exchange
- FUNC Nasdaq
- IVA Nasdaq
- Market Cap
- FUNC N/A
- IVA 162.8M
- IPO Year
- FUNC N/A
- IVA 2020
- Fundamental
- Price
- FUNC $29.69
- IVA $2.91
- Analyst Decision
- FUNC
- IVA Strong Buy
- Analyst Count
- FUNC 0
- IVA 4
- Target Price
- FUNC N/A
- IVA $13.25
- AVG Volume (30 Days)
- FUNC 17.6K
- IVA 8.5K
- Earning Date
- FUNC 04-22-2025
- IVA 03-26-2025
- Dividend Yield
- FUNC 2.94%
- IVA N/A
- EPS Growth
- FUNC 40.00
- IVA N/A
- EPS
- FUNC 3.15
- IVA N/A
- Revenue
- FUNC $76,870,000.00
- IVA $15,243,814.00
- Revenue This Year
- FUNC $13.86
- IVA $18.05
- Revenue Next Year
- FUNC $8.36
- IVA $46.74
- P/E Ratio
- FUNC $9.77
- IVA N/A
- Revenue Growth
- FUNC 10.26
- IVA N/A
- 52 Week Low
- FUNC $19.17
- IVA $1.53
- 52 Week High
- FUNC $42.50
- IVA $3.98
- Technical
- Relative Strength Index (RSI)
- FUNC 35.25
- IVA 51.16
- Support Level
- FUNC $29.08
- IVA $2.70
- Resistance Level
- FUNC $31.03
- IVA $3.10
- Average True Range (ATR)
- FUNC 0.99
- IVA 0.19
- MACD
- FUNC 0.06
- IVA -0.02
- Stochastic Oscillator
- FUNC 21.63
- IVA 46.66
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.